Effectiveness of pharmaceutical care for drug treatment adherence in women with lupus nephritis in Rio de Janeiro,Brazil: a randomized controlled trial
Restricted accessResearch articleFirst published online October, 2019
Effectiveness of pharmaceutical care for drug treatment adherence in women with lupus nephritis in Rio de Janeiro,Brazil: a randomized controlled trial
Studies have been conducted to determine the causal factors and clinical consequences of non-adherence to treatment in systemic lupus erythematosus (SLE). However, no interventions have been performed to increase drug adherence. Our objective was to assess the effectiveness of pharmaceutical care (PC) for drug treatment adherence in lupus nephritis (LN).
Methods
This was a randomized clinical trial (pragmatic trial) in patients with LN in Rio de Janeiro, Brazil, allocated in two groups: an intervention group (Dader Method for PC) and a control group (institution's usual care). Drug treatment adherence was measured by the combination of five questions normally used in clinical practice.
Results
A total of 131 patients were randomized, and 122 completed the study, with a mean follow-up of 12.7 months and use of six drugs per day and 10–12 doses per day. Low adherence was observed at baseline (intervention group: 30%; control group: 29%). PC showed 27% effectiveness (95% confidence interval (CI) –6% to 50%) in the intention to treat analysis and 31% (95% CI 0–52%) in per protocol analysis, considering all drugs. As for adherence to specific drugs for SLE, effectiveness of PC was 64% (95% CI 34–80%) with intention-to-treat analysis and 62% (95% CI 32–79%) in per protocol analysis.
Conclusions
PC was effective for increasing drug treatment adherence in SLE. The detailed account provided by the Dader Method of the difficulties with patients' drug therapy proved invaluable to approach non-adherence.
KlumbEMSilvaCAALannaCCD, et al.Consensus of the Brazilian Society of Rheumatology for the diagnosis, management and treatment of lupus nephritis. Rev Bras Reumatol2015; 5: 1–21.
2.
MehatPAtiquzzamanMEsdaileJMAviña-ZubietaAVeraMA. Medication nonadherence in systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken)2017; 69: 1706–1713.
3.
FeldmanCHYazdanyJGuanHSolomonDHCostenbaderKH. Medication nonadherence is associated with increased subsequent acute care utilization among Medicaid beneficiaries with systemic lupus erythematosus. Arthritis Care Res (Hoboken)2015; 67: 1712–1721.
4.
Costedoat-ChalumeauNPouchotJGuettrot-ImbertG, et al.Adherence to treatment in systemic lupus erythematosus patients. Best Pract Res Clin Rheumatol2013; 27: 329–340.
5.
GaloJSMehatPRaiSKAviña-ZubietaAVeraMA. What are the effects of medication adherence interventions in rheumatic diseases: a systematic review. Ann Rheum Dis2016; 75: 667–673.
6.
Stuurman-BiezeAGHiddinkEGvan BovenJF, et al.Proactive pharmaceutical care interventions decrease patients' nonadherence to osteoporosis medication. Osteoporos Int2014; 25: 1807–1812.
7.
CostaEGiardiniASavinM, et al.Interventional tools to improve medication adherence: review of literature. Patient Prefer Adherence2015; 9: 1303–1314.
8.
PandeSHillerJENkansahN, et al.The effect of pharmacist-provided non-dispensing services on patient outcomes, health service utilization and costs in low-and middle income countries. Cochrane Database Syst Rev2013, pp. CD010398.
9.
ChumneyECRobinsonLC. The effects of pharmacist interventions on patients with polypharmacy. Pharmacy Pract (Granada)2006; 4: 103–109.
10.
MelchiorsACCorrerCJVensonRPontaroloR. An analysis of quality of systematic reviews on pharmacist health interventions. Int J Clin Pharm2012; 34: 32–42.
11.
HaynesRBAcklooESahotaNMcDonaldHPYaoX. Interventions for enhancing medication adherence. Cochrane Database Syst Rev2008, pp. CD000011.
12.
TingTVKudalkarDNelsonS, et al.Usefulness of cellular text messaging for improving adherence among adolescents and young adults with systemic lupus erythematosus. J Rheumatol2012; 39: 174–179.
13.
GanachariMSAlmasSA. Evaluation of clinical pharmacist mediated education and counselling of systemic lupus erythematosus patients in tertiary care hospital. Ind J Rheumatol2012; 7: 7–12.
14.
Machuca M, Fernández-Llimós F, Faus MJ. Método Dáder. Guía de Seguimiento Farmacoterapêutico. Granada, Spain: Universidad de Granada, 2003.
15.
Oliveira-SantosMVeraniJFSCamachoLABAndradeCAFFerrante-SilvaRKlumbEM. Effectiveness of pharmaceutical care for drug treatment adherence in patients with systemic lupus erythematosus in Rio de Janeiro, Brazil: study protocol for a randomized controlled trial. Trials2016; 17: 181–190.
16.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725.
17.
PetriMOrbaiAMAlarcoGS, et al.Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum2012; 64: 2677–2686.
18.
WeeningJJD'AgatiVDSchwartzMM, et al.The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol2004; 15: 241–250.
19.
AbramsonJH. WINPEPI updated: computer programs for epidemiologists, and their teaching potential. Epidemiol Perspect Innov2011; 8: 1.
20.
SilvaCCanhãoHBarcelosAMirandaLPintoPSantosMJ. Protocolo de avaliação e monitorização do Lúpus Eritematoso Sistêmico (PAMLES). Acta Reumatol Port2008; 33: 210–218.
21.
GriffithsBMoscaMGordanC. Assessment of patients with systemic lupus erythematosus and the use of lupus disease activity indices. Best Pract Res Clin Rheumatol2005; 19: 685–708.
22.
UribeAGViláLMMcgwinGJrSanchezMLReveilleJDAarcónGS. The Systemic Lupus Activity Measure-Revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol2004; 31: 1934–1940.
23.
MoriskyDEAngAKrousel-WoodMWardHJ. Predictive validity of a medication adherence measure in an outpatient setting. J Clin Hypertens2008; 10: 348–354.
24.
Oliveira-FilhoADMoriskyDENevesSJFCostaFALyra JuniorDP. The 8-item Morisky Medication Adherence Scale: validation of a Brazilian–Portuguese version in hypertensive adults. Res Social Adm Pharm2014; 10: 554–561.
25.
GarfieldSCliffordSEliassonLBarberNWillsonA. Suitability of measures of self-reported medication adherence for routine clinical use: a systematic review. BMC Med Res Methodol2011; 11: 149.
26.
DelgadoABLimaML. Contributo para a validação concorrente de uma medida de adesão aos tratamentos. Psico Saúde e Doença2001; 2: 81–100.
27.
HughesLDDoneJYoungA. A 5 item version of the Compliance Questionnaire for Rheumatology (CQR5) successfully identifies low adherence to DMARDs. BMC Musculoskelet Disord2013; 14: 286–294.
28.
Scheiman-ElazaryADuanLShourtC, et al.The rate of adherence to antiarthritis medications and associated factors among patients with rheumatoid arthritis: a systematic literature review and metaanalysis. J Rheumatol2016; 43: 512–523.
29.
WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment, http://www.whocc.no/atc_ddd_index (accessed 10 March 2016).
30.
Oliveira-SantosMVeraniJFSKlumbEMAlbuquerqueEMN. Evaluation of adherence to drug treatment in patients with systemic lupus erythematosus in Brazil. Lupus2011; 20: 320–329.
31.
World Health Organization. Adherence to long-term therapies: evidence for action, Geneva, Switzerland: World Health Organization, 2003.
Fletcher RH, Fletcher SW, Fletcher GS. Clinical epidemiology: the essentials. 5th ed. Baltimore, MD: Wolters Kluwer/Lippincott Williams & Wilkins, 2014.
34.
BoutronIMoherDAltmanDGSchulzKFRavaudP. Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments. Ann Intern Med2008; 148: W60–W66.
35.
R Foundation for Statistical Computing. R: A language and environment for statistical computing, https://www.R-project.org (accessed 23 March 2016).
Obreli-NetoPRGuidoniCMBaldoniCM, et al.Effect of a 36-month pharmaceutical care program on pharmacotherapy adherence in elderly diabetic and hypertensive patients. Int J Clin Pharm2011; 33: 642–649.
38.
CharroisTLZolezziMKoshmanSL, et al.A systematic review of the evidence for pharmacist care of patients with dyslipidemia. Pharmacotherapy2012; 32: 222–223.
39.
LeeJKGraceKATaylorAJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA2006; 296: 2563–2571.
LenanderCElfssonBDanielssonBMidlovPHasselstromJ. Effects of a pharmacist-led structured medication review in primary care on drug related problems and hospital admission rates: a randomized controlled trial. Scand J Prim Health Care2014; 32: 180–186.
42.
ReisTMCamposMSANagaiMMPereiraLRL. Contributions of pharmacists in the treatment of epilepsy: a systematic review. Am J Pharm Benefits2016; 8: e55–e60.
43.
KumarKGordonCToescuV, et al.Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of South Asian and white British origin. Rheumatology2008; 47: 690–697.
44.
ConnVSRupparTMMaithe EnriquezRCooperPS. Patient-centered outcomes of medication adherence interventions: systematic review and meta-analysis. Value Health2016; 19: 277–285.
45.
RottaISalgadoTMSilvaMLCorrerJCFernandez-LlimosF. Effectiveness of clinical pharmacy services: an overview of systematic reviews (2000–2010). Int J Clin Pharm2015; 37: 687–697.
46.
StirrattMJDunbar-JacobJCraneHM, et al.Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med2015; 5: 470–482.
